期刊文献+

普拉格雷含量及有关物质的测定 被引量:5

Determination of the Content of Prasugrel and Its Related Substances
下载PDF
导出
摘要 采用 HPLC法测定了普拉格雷原料药含量和有关物质。色谱条件如下:色谱柱为 C18柱(150 mm×4.6 mm,5μm),柱温30℃,流动相为乙腈-磷酸盐缓冲溶液(pH 值5.0)(50∶50,体积比),流速1.0 mL·min-1,检测波长219 nm,进样量10μL。结果表明:普拉格雷在0.5~3.0μg·mL-1范围内,线性关系良好,平均加样回收率为99.95%(n=9)。此法操作简便、快速、灵敏、准确,样品处理简便易行,可用于测定普拉格雷原料药含量和有关物质。 A HPLC method for determination of the content of Prasugrel and its related substances was es-tablished.The chromatographic conditions were conducted as follows:Diamonsil C18 column(150 mm×4.6 mm, 5μm)with the temperature of 30 ℃,mobile phase consisting of acetonitrile∶phosphate buffer (pH value 5.0) in the volume ratio of 50∶50,the flow rate of 1.0 mL·min-1 ,the detection wavelength of 219 nm,the injection volume of 10μL .The calibration curve for Prasugrel was linear in the range of 0.5~3.0μg·mL-1 .The aver-age of recovery rate was 99.95%(n=9).The method was rapid,simple,accurate,sensitive and suitable for de-termination of the content of Prasugrel and its related substances.
作者 刘娥
出处 《化学与生物工程》 CAS 2014年第7期76-78,共3页 Chemistry & Bioengineering
基金 湖北省教育厅科研项目(Q20134302)
关键词 HPLC 普拉格雷 有关物质 含量 HPLC Prasugrel related substances content
  • 相关文献

参考文献5

二级参考文献17

  • 1Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile [J]. Cardiovascular Drug Rev, 2007, 25 (4) : 357-374.
  • 2Alain B, Daniel F, Jean-Pierre M, et al. Derivatives of alpha- (2-oxo-2,4,5,6,7,7a-hexahydrothieno [3,2-c]-5- pyridyl)phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitiors: US, 4740510 [P]. 1988-04-26. (CA 1986, 107: 89900)
  • 3Hiroyuki K, Fumitoshi A, Atsuhiro S, et al. Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation: EP, 0542411 [P]. 1993-05-19. (CA 1993, 120: 8583)
  • 4JAKUBOWSKI JA, WINTERS KJ, NAGANUMA H, et al. Prasugrel:a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis forits distinct antiplatelet profile [ J ]. Cardiovascular Drug Rev, 2007,25 (4) : 357 - 374.
  • 5HIROYUKI K, FUMITOSHIA, ATSUHIRO S, et al. Tetrahydrothienopyridine derivatives,furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation: EP,0542411 [ P]. 1993 -05 - 19.
  • 6KIKUO A, HIROYUKI M, MASAHIKO K, et al. 2-silyloaytetrahydropiridine, salt thereof and process for producing the same: EP, 0785205A1 [ P]. 1997 -07 -23.
  • 7ASHOK K, KETAN DHANSUKHLAL V, SANJAY GOVIND B, et al. Industrial process for preparation of clopidogrel hydrogen sulphate : WO, 104663 [ P]. 2005 - 11 - 10.
  • 8ALAIN B, DANIEL F, JEAN-PIERRE M, et al. Derivatives of alpha- ( 2-oxo -2,4,5,6,7,7 a-hexabydrothieno [ 3,2-c ] -5 -pyridyl) phenyl acetic acid and their use as platelet and thrombotic aggregation inhibitiors : US ,4740510 [ P ]. 1988 - 04 - 26.
  • 9Mitakos A,Panderi I.A validated LC method for the determination of clopidogrel in pharmaceutical preparations[J].J Pharm Biomed Anal,2002,28(3-4):431-438.
  • 10国家药典委员会.中华人民共和国药典二部附录(2005年版)[M].北京:化学工业出版社,2005:28-30.

共引文献26

同被引文献44

  • 1何媛,王四旺,吴红.桉油β-环糊精包合物的制备与鉴定[J].中国药房,2006,17(4):255-258. 被引量:20
  • 2张姝,聂淑芳,魏兰兰,吴静,于飞千,潘卫三.格列吡嗪与2种环糊精衍生物在水溶液中包合作用的研究[J].中国新药杂志,2007,16(6):466-469. 被引量:3
  • 3Lambropoulos J, Bergholdt AB. Method development and validation for the HPLC potency assay of prasugrel tablets [ J ]. J Pharm Bi- omed Anal,2000,24(2) :251 -258.
  • 4R Kishore Reddy Seerapu, Venkateswara Rao A, Lavanya P, et al. Development of Validation RP - HPLC Method For The Estimation of Prasugrel HC1 in Pure and Pharmaceutical Formulat- ions[ J]. Journal of Pharmacy Research, 2011,4 ( 9 ) : 3105 - 3107.
  • 5William Baker,C. White.Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes[J]. American Journal of Cardiovascular Drugs . 2009 (4)
  • 6Pia Thybo,Jakob Kristensen,Lars Hovgaard.Characterization and Physical Stability of Tolfenamic Acid-PVP K30 Solid Dispersions[J]. Pharmaceutical Development and Technology . 2007 (1)
  • 7Christian Leuner,Jennifer Dressman.Improving drug solubility for oral delivery using solid dispersions[J]. European Journal of Pharmaceutics and Biopharmaceutics . 2000 (1)
  • 8V Tantishaiyakul,N Kaewnopparat,S Ingkatawornwong.Properties of solid dispersions of piroxicam in polyvinylpyrrolidone[J]. International Journal of Pharmaceutics . 1999 (2)
  • 9SRIMIVAS RAVV,JALINDAR J,SRINIVAS G,et al.Process for the preparation of 2-acetoxy-5- (α-cycloprpylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine. WO,2009122440 . 2009
  • 10Ansari Muhammad Tayyab,Batty Kevin T,Iqbal Ijaz,Sunderland Vivian Bruce.Improving the solubility and bioavailability of dihydroartemisinin by solid dispersions and inclusion complexes. Archives of Pharmacal Research . 2011

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部